北京若生智能科技有限公司
Drug Database
NA

nabilone (Canemes)

✓ Approved

AOP Health · CNR1

什么是 nabilone？

nabilone 是一种治疗药物，由AOP Health研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Canemes
公司AOP Health
分子靶点CNR1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, AOP Health

作用机制

分子靶点

nabilone 作用于 1 个分子靶点：

CNR1cannabinoid receptor 1 (CNR, CB1A)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

相关研究文献

PubMedBiotech (Basel (Switzerland))2026-10-26

Pharmaceutical Residues in Human Urine from Patients Under Antiretroviral Regimens and Self-Reported Healthy Individuals Before and After Three Months' Storage: Implication for Agricultural Reuse in Pretoria, South Africa.

Lizbelt Mugivhisa Liziwe ML, Faith Baloyi Khanyi BK, Oladeji Oluwaseun Mary OM, Olatunji Olatunde Stephen OS et al.

Background/Objectives: Pharmaceutical residues in human urine have raised serious concerns about the safe reuse of urine in agriculture. The current study investigates and compares the concentrations of pharmaceuticals in urine samples collected from male patients undergoing active antiretroviral regimens and self-reported "healthy individuals" at a government hospital in Pretoria, South Africa, and determines how the residues changed during three months of ambient storage, which is the usual recommendation before use in agriculture. Methods: The urine samples were collected in a plastic bottle to prevent fecal contamination, and 15 targeted compounds were analyzed using solid-phase extraction and liquid chromatography-mass spectrometry. The linearity ranged from 0.9910 to 0.9999, 75.5% to 99.1% for recovery, and intra-day and inter-day precision were below 6%. The urine from each group was collected into one pooled sample and then analyzed both pre- and post-storage. Results: Thirteen pharmaceuticals were detected in urine from patients on regular medication before storage; in "healthy individuals", detections rose from eight to twelve after storage. Concentrations in the composite samples after storage were higher for some of the compounds but lower for others, including caffeine, nevirapine, prednisolone and 17α-ethinylestradiol. Metformin was highest overall at 1186.25 µg/L and remained at 806.68 µg/L after storage. The highest concentration for all the pharmaceuticals was reported for metformin, with a value of 1186.25 µg/L, occurring in the group of patients on a regular regimen. There could be a possibility that the rise can be attributed to the hydrolysis of conjugated metabolites during storage; however, no analysis of conjugates was carried out. Conclusions: This study shows the need for appropriate treatment of human urine prior to its reuse as fertilizer and echoes the importance of further research into human exposure pathways and effective pharmaceutical removal strategies.

PMID 42930069
阅读全文 →
PubMedInorganic chemistry2026-10-26

Terminal Oxygen as a Proton Acceptor: S-H Activation via Proton-Coupled Electron Transfer in Decavanadate-Catalyzed P(O)-S Coupling.

Wang Li Li LL, Shu Wei-Xuan WX, Wang Ya Y, Zhong Rong-Lin RL et al.

Polyoxometalates-catalyzed P-S oxidative coupling under mild conditions has emerged as a promising sustainable route to thiophosphates for pharmaceuticals and agrochemicals. This work reveals that the decavanadate cluster-catalyzed oxidative coupling between phosphine oxide and thiophenol involves four elementary steps, in which the rate-determining step is S-H bond activation via proton-coupled electron transfer (PCET). The polyoxovanadate cluster acts as a proton relay station, stabilizing the key proton in the transition state and facilitating its transfer. Interestingly, the proton preferentially transfers to a terminal oxygen rather than a bridging oxygen, with simultaneous electron transfer to the adjacent vanadium center. The terminal oxygen atom is more reactive than the bridging one because the [H3V10VO28]3- skeleton incurs a smaller electronic reorganization penalty for electron transfer in the terminal oxygen via a PCET pathway. On the other hand, the preferential activation of the S-H bond over the P-H bond in the [H3V10VO28]3--catalyzed reaction arises from both the smaller S-H bond dissociation energy and the better orbital energy match with the thiol substrate. These findings provide a theoretical foundation for understanding PCET in polyoxometalate catalysis and expanding the application of POMs in organic synthesis.

PMID 42929611
阅读全文 →
PubMedEnvironmental geochemistry and health2026-10-26

HDL-C as a mediator of PPCP-related kidney function decline in community-dwelling elderly: a mixture analysis approach.

Zhao Yutong Y, Wang Sheng S, Zhou Luoling L, Xu Yuanyuan Y et al.

Pharmaceuticals and personal care products (PPCPs) are widespread environmental contaminants, but their associations with kidney function and lipid metabolism remain incompletely understood. This study included 2758 adults aged ≥ 60 years in Anhui Province, China, during 2022-2023 and used a cross sectional design. Urinary concentrations of 48 PPCPs and two metabolites were measured using high-performance liquid chromatography-tandem mass spectrometry. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Individual associations were assessed using logistic and linear regression, and mixture associations using weighted quantile sum (WQS) regression and Bayesian kernel machine regression. Restricted cubic splines examined nonlinear associations, and exploratory mediation analyses assessed the statistical contribution of high-density lipoprotein cholesterol (HDL-C). Among nine PPCPs with detection frequencies > 50%, doxycycline, enrofloxacin, acetaminophen, metformin, and cotinine were associated with lower eGFR after full adjustment and Benjamini-Hochberg correction. Coefficients ranged from - 3.00 to - 0.93 mL/min/1.73 m2 per tenfold increase in urinary concentration. Tylosin and caffeine were positively associated with eGFR. The WQS index was inversely associated with eGFR, with metformin receiving the largest weight. HDL-C showed a positive nonlinear association with eGFR. Under the mediation model assumptions, HDL-C statistically accounted for 12.21-29.30% of the associations involving enrofloxacin, metformin, and acetaminophen, and 13.78% of the mixture association. The indirect association for cotinine was nonsignificant. These findings remain exploratory. Prospective studies are needed to clarify temporal relationships and address possible reverse causation.

PMID 42928303
阅读全文 →
PubMedBMC chemistry2026-10-26

Development and validation of the analytical method for determination of residual solvents (2-propanol and n-hexane) in the drug substance Inosine Pranobex.

Chemna Khrystyna K, Logoyda Liliya L, Rudiuk Vitalii V

Monitoring residual solvents in active pharmaceutical ingredients (APIs) is critical due to their potential toxicity and impact on the physicochemical stability of the final medicinal product. Therefore, strict control of these impurities is a mandatory requirement to ensure patient safety and maintain compliance with international pharmacopoeia standards and good manufacturing practices (GMP). The goal of this study was to develop and validate a sensitive method for the determination of two residual solvents using headspace gas chromatography with flame ionization detector (HS-GC-FID) in Inosine Pranobex API according to The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. A mixture of water and N, N-dimethylformamide (5:1) was selected as the sample solvent. To achieve high resolution between nonpolar n-hexane and polar 2-propanol, the method was implemented using a DB-624 (60 m × 0.25 mm × 1.4 μm) chromatographic column with an oven temperature program and at a flow rate of 35 cm/s. Equilibration time of the samples was 20 min at temperature 105 °С, total run time was 43 min. The analytical method complied with the established requirements during validation. The limit of quantification was confirmed for 2-propanol - 30 ppm, for n-hexane - 1 ppm. The developed method provides guaranteed purity and safety of the drug substance and is a reliable tool for controlling residual solvents at the drying stage of the technological process of synthesizing the drug substance Inosine Pranobex.

PMID 42928349
阅读全文 →
PubMedDrugs in R&D2026-10-26

Biochemical Characterization and Stability of a New Fibrinogen Concentrate (BT524) Manufactured Using an Innovative Virus Inactivation Step.

Schulte Linda L, Fürtig Boris B, Scheich Christoph C, Kistner Steffen S et al.

Human plasma is utilized in the production of life-saving pharmaceuticals, including fibrinogen, a key player in clot formation, tissue repair, and hemostasis. Fibrinogen deficiency results in impaired blood clotting and potentially severe hemorrhagic events. Fibrinogen concentrate or cryoprecipitate are the preferred options for fibrinogen replacement therapy. Both increase plasma fibrinogen levels, but utilization of fibrinogen concentrate is advantageous. It offers enhanced pathogen safety through manufacturing procedures that remove or inactivate viruses or prions potentially present in human plasma. We developed a novel manufacturing process that yields a fibrinogen concentrate (BT524) and coagulation factor VIII (Haemoctin® SDH) in one workflow. This process contains several virus inactivation steps, including an innovative UV-C irradiation and a cation exchange chromatography (CEX) step for prion removal. While successfully inactivating potential viral contamination, UV-C irradiation showed no influence on fibrinogen structure and composition, and no formation of neoantigenic structures could be identified. Fibrinogen concentrate (BT524) contained almost exclusively fibrinogen with activity close to 100%, very low numbers of sub-visible particles and lacked measurable thrombogenic activity. The stability study of clinical material demonstrated a stable product for five years under several storage conditions. With a solubility at room temperature of 2-4 min upon reconstitution using the nextaro®v transfer device, the fibrinogen concentrate is almost immediately ready to use. The reconstituted solution demonstrated physico-chemical stability for 24 h. Fibrinogen concentrate (BT524) generated using the novel manufacturing process yielded a product of high quality, purity and virus safety. In addition, it offers excellent solubility, long-term stability and high activity. The integration of shared process steps with Haemoctin® SDH facilitates a more ethical and efficient utilization of human blood plasma. In clinical trials, the potency, safety and tolerability of the manufactured fibrinogen concentrate were demonstrated.

PMID 42928403
阅读全文 →
PubMedBMC surgery2026-10-26

Novel self-assembling peptide gel CK2-085-SP (SPG-178) as a sealant for preventing postoperative pancreatic fistula after pancreatic resection: a study protocol for a prospective, exploratory, investigator-initiated clinical trial (PepSeal-001).

Tomimaru Yoshito Y, Shigeno Satoshi S, Shirakura Kenji K, Harada Airi A et al.

Postoperative pancreatic fistula (POPF) remains a critical complication following pancreatic resection. Standard fibrin sealants are frequently degraded by pancreatic proteases, limiting their efficacy, which is hypothesized to be due to rapid degradation by proteolytic enzymes in pancreatic juice. CK2-085-SP is a novel, synthetic self-assembling peptide (SPG-178) gel that retains its structural integrity in pancreatic juice, potentially providing more robust sealing than conventional biological sealants. We designed this exploratory, investigator-initiated trial to evaluate the safety and feasibility of CK2-085-SP. This study represents the first-in-human clinical application of the self-assembling peptide gel for pancreatic resection. This is a prospective, single-arm clinical trial (PepSeal-001) for which the Clinical Trial Notification has been accepted by the Pharmaceuticals and Medical Devices Agency. A total of 25 patients will be enrolled to ensure that CK2-085-SP is applied to at least 10 patients undergoing pancreaticoduodenectomy and 10 patients undergoing distal pancreatectomy. To ensure the evaluation of the device in high-risk cases, the study aims to include at least seven patients undergoing pancreaticoduodenectomy with a main pancreatic duct diameter ≤ 3 mm. The primary endpoints are the incidence and severity of adverse events and device malfunctions within 90 days postoperatively. Secondary endpoints include amylase levels in drainage fluid; the incidence of clinically relevant POPF; incidence of intra-abdominal abscess, delayed gastric emptying, postoperative hemorrhage, drainage tube reinsertion, reoperation, readmission, and postoperative mortality; duration of drain placement; length of postoperative hospital stay; and usability of the study device. The PepSeal-001 trial will evaluate the safety and feasibility of CK2-085-SP in pancreaticoduodenectomy and distal pancreatectomy. This study is expected to provide clinical evidence for the development of a novel synthetic peptide-based sealant to improve outcomes in pancreatectomy.

PMID 42928181
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nabilone